Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

1.78
+0.03001.71%
Post-market: 1.76-0.0154-0.87%19:57 EDT
Volume:230.62K
Turnover:406.57K
Market Cap:8.53M
PE:-0.77
High:1.79
Open:1.75
Low:1.73
Close:1.75
52wk High:2.68
52wk Low:0.8400
Shares:4.79M
Float Shares:4.78M
Volume Ratio:2.16
T/O Rate:4.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3210
EPS(LYR):-11.3245
ROE:-163.23%
ROA:-76.44%
PB:1.47
PE(LYR):-0.16

Loading ...

Alzamend Neuro Director Lynne Fahey Mcgrath Dies

Reuters
·
Jul 22

Alzamend Neuro Inc Expected to Post a Loss of 67 Cents a Share - Earnings Preview

Reuters
·
Jul 18

Alzamend Neuro Shareholders Approve Governance and Capital Measures

TIPRANKS
·
Apr 18

Alzamend Neuro shareholders approved reverse stock split proposal at annual meeting

Reuters
·
Apr 18

Top Insider Makes Bold New Move on Alzamend Neuro Stock

TIPRANKS
·
Apr 17

Alzamend Neuro director Milton C. Ault III acquires 108,388 shares for $108,897

Reuters
·
Apr 17

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)

TIPRANKS
·
Apr 08

Alzamend reports encouraging Phase II brain MRS data for AL001 lithium therapy

Reuters
·
Apr 07

Alzamend Neuro Reports Encouraging Pharmacodynamic Data From Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

THOMSON REUTERS
·
Apr 07

Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate

Reuters
·
Mar 26

Alzamend Neuro Reports Positive Topline Data From Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study; Al001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Al001 Shows Higher Lithium Concentrations in All Measured Brain Regions

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Initiates Second Phase Ii Trial in Bd Patients; Topline Data Expected Q3 2026

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Additional Phase Ii Studies in Mdd, Ptsd, Alzheimer's Expected to Begin in Latter Half of 2026

THOMSON REUTERS
·
Mar 26

Alzamend Neuro Inc - Al001 Delivers 101% Total Lithium Blood Exposure, 97% Peak Levels VS Standard Carbonate

THOMSON REUTERS
·
Mar 26

Alzamend Neuro faces Nasdaq delisting risk as stockholders’ equity falls to 2.2 million USD

Reuters
·
Mar 21